Author

Pingshan Guo

Observed name: P Guo

Institution: Second Military Medical University

Observed institutions: Second Military Medical University, Shanghai Changzheng Hospital, Celgene (United States)

OpenAlex ID: A5079822384

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)

2008 · Pier Luigi Zinzani, Thomas E. Witzig, et al. · Blood · 35

Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

2009 · Thomas E Witzig, Julie M. Vose, et al. · Blood · 13

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003)

2008 · Myron S. Czuczman, Julie M. Vose, et al. · Blood · 7

The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).

2008 · Craig B. Reeder, T.E. Witzig, et al. · Blood · 4

[A case-control study of multiple myeloma patients with central nervous system involvement].

2022 · L Li, Z Y Feng, et al. · PubMed

[The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].

2021 · J Liu, H Y He, et al. · PubMed

Works count: 6

Citation count: 59

H-index: 4

I10-index: 2